Video

Dr. Smith Discusses the Diagnosis of Double-Hit Lymphoma

Sonali M. Smith, MD, Elwood V. Jensen Professor in Medicine, director, Lymphoma Program, University of Chicago Medicine, discusses the diagnosis of double-hit lymphoma.

Sonali M. Smith, MD, Elwood V. Jensen Professor in Medicine, director, Lymphoma Program, University of Chicago Medicine, discusses the diagnosis of double-hit lymphoma.

The presence of double-hit lymphoma is relatively uncommon, Smith says, with an incidence of about 5% to 7% in all unselected cases. This is a lot of unselected patients to test by multiple fluorescence in-situ hybridization (FISH) probes to identify a very few number of double-hit cases with a very poor prognosis.

There are different approaches to screening that limit the number of patients who need FISH testing, says Smith. Double-hit lymphoma primarily occurs in patients who have germinal center diffuse large B-cell lymphoma, so some have suggested using the cell-of-origin model to decide which patients need further FISH testing. Another approach is identifying a dual expression of MYC and BCL-2. Smith says that currently, there is no information on which of those will be most cost effective or rational.

Related Videos
Lajos Pusztai, MD, DPhil
Hope S. Rugo, MD
Marc Machaalani, MD
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Alfred L. Garfall, MD, MS
Razane El Hajj Chehade, MD
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Coral Olazagasti, MD
Barbara Jane O’Brien, MD, associate professor, Neuro-Oncology, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center